Composition for improving skin barrier or elasticity

Abstract

The present disclosure relates to a composition for improving skin barrier or elasticity. The composition for improving skin barrier or elasticity of the present disclosure has a remarkably excellent synergistic effect in improving skin barrier or elasticity through the combination between specific effective ingredients, and thus can be effectively used as a functional composition in a cosmetic or a skin external agent targeting skin tissue.

Description

Technical Field

[0001] This application claims priority based on Korean Application No. 10-2024-0027528, filed on February 26, 2024, the entire contents of which are disclosed in the specification and drawings of that application are incorporated herein by reference.

[0002] This disclosure relates to compositions for improving the skin barrier or elasticity. Background Technology

[0003] The skin acts as a barrier, protecting the body from external environmental influences and preventing the loss of internal moisture and beneficial substances. Furthermore, the skin is a vital organ responsible for various physiological functions, including thermoregulation and excretion. However, due to factors such as the following, skin cell activity may decrease, leading to a deterioration in skin condition.

[0004] Collagen and elastin, found in the dermis, significantly influence skin structure by maintaining its mechanical strength, the resistance of connective tissue, tissue cohesion, and supporting cell adhesion. Collagen decreases due to stress, aging, or photoaging caused by UV exposure. Furthermore, elastin's three-dimensional structure is reportedly distorted due to increased elastase activity after UV exposure. Consequently, with the reduction of collagen and the decrease in elastin activity, skin tissue becomes loose and loses its elasticity.

[0005] Reduced cellular function in the epidermis hinders metabolism and reduces the likelihood of shedding, leading to excessive buildup of dead skin cells. In this state, exposure to ultraviolet radiation reduces skin elasticity, resulting in wrinkles. Alternatively, when the epidermis fails to form a sebum film, reduced moisture and sebum secretion leads to dry skin, which can also cause wrinkles.

[0006] Sebum, sweat, or cosmetic ingredients can be broken down into highly toxic substances by resident bacteria on the skin, irritating it and inducing inflammation. Additionally, ultraviolet radiation can increase the production of nitric oxide (NO), an inflammatory mediator, in the skin, thus triggering skin problems. Most of the nitric oxide production is caused by inactive nitrogen oxides (iNOS), which are reportedly rapidly induced by stimuli such as LPS or cytokines, leading to excessive NO production.

[0007] Reactive oxygen species (ROS), also known as harmful oxygen species, are toxic substances produced in cells through physiological processes such as respiration. They are constantly generated and eliminated, and exist at approximately 3-5% under normal conditions. These ROS are primarily composed of superoxide radicals (O2).- ), hydroxyl radical (HO) + Reactive oxygen species (ROS) exist as free radicals (chemically, unpaired atoms or molecules in their outermost electron orbitals, which are highly unstable and reactive) or as compounds with paired electrons, such as hydrogen peroxide (H₂O₂) or singlet oxygen (singlet radical). While ROS have the advantage of acting as a biological defense mechanism by killing bacteria within physiological systems, they often cause oxidation within organisms, thus playing a harmful role as a cause of disease. It has been reported that ROS attack biomolecules, thereby damaging cells or tissues and triggering various diseases involved in aging or other adult-onset diseases.

[0008] Research continues to develop substances that inhibit skin aging caused by the aforementioned factors, improve wrinkles, elasticity, and other skin problems, and possess antioxidant effects. Substances with beneficial effects on the skin are widely distributed in nature, primarily using natural plant-derived substances as raw materials in food, cosmetics, and pharmaceuticals. However, the effects of these natural substances are limited, requiring large-scale use to achieve meaningful results, leading to issues of toxicity and rising prices.

[0009] To address the problems associated with natural substances, the development of chemically synthesized substances continues. Compared to natural substances, these chemically synthesized substances have the advantage of exhibiting significantly superior effects even when used in small quantities. However, they also pose a risk of causing various serious side effects on the human body, thus limiting their use.

[0010] Therefore, there is a need to develop a new substance that is derived from natural sources, ensures stability, and has excellent effects on improving the skin. Summary of the Invention

[0011] Technical issues

[0012] The problem to be solved by this disclosure is to provide a skin improvement composition that improves the side effects or precautions of existing skin improvement agents, does not have the disadvantages of weak effects of skin improvement agents, is safe for the human body and has excellent effects on improving the skin barrier or elasticity.

[0013] Technical solution

[0014] To address the aforementioned problems, the inventors of this disclosure conducted intensive research and efforts, resulting in the discovery that PDRN (polydeoxyribonucleotide); and combinations of any one or more of troxerutin, panthenol, arachidyl glucoside, and Chondrus crispus extract promote the improvement of the skin barrier or elasticity. In particular, compared to using individual ingredients, the combination of the above-described ingredients surprisingly demonstrates a significant synergistic effect in improving the skin barrier and elasticity, thus completing this invention.

[0015] This disclosure provides a composition for improving skin barrier or elasticity, comprising PDRN and one or more selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside and carrageenan extract as active ingredients.

[0016] In one aspect of this disclosure, the PDRN, as a DNA fragment, can be a transparent liquid. The PDRN can be extracted from various animals or plants, such as from the testes of salmonid fish, gardenia mushrooms, or oats. In one aspect of this disclosure, the PDRN can be obtained by filtration through a 0.3 to 1 μm filter, preferably 0.4 to 0.5 μm. In one aspect of this disclosure, the average molecular weight of the PDRN can be 5 to 4000 kDa, preferably 20 to 2000 kDa, more preferably 50 to 1000 kDa. In one aspect of this disclosure, the composition can contain a DNA fragment called a polynucleotide (PN), and a polynucleotide with the same extraction conditions and average molecular weight as the PDRN can be used.

[0017] In one aspect of this disclosure, the aforementioned troxerutin is also known as vitamin P4, and its compound name is 3',4',7'-tri[O-(2-hydroxyethyl)]rutin, which is derived from the Sophora japonica tree ( Sophora japonica Troxerutin is a natural flavonoid obtained from [the source of the substance]. It is one of the stable bioflavonoids known to have anti-inflammatory effects by inhibiting lipoxygenase and prostaglandin formation. Additionally, troxerutin can help maintain healthy blood and lymphatic microcirculation by regulating capillary resistance, thereby stabilizing the skin. Furthermore, troxerutin has the effect of protecting skin cells from cell death, cell migration restriction, growth arrest, or DNA damage induced by ultraviolet radiation in skin cells.

[0018] In one aspect of this disclosure, the aforementioned panthenol is a precursor of vitamin B5, which is broken down in the body and converted into pantothenic acid. Panthenol is well known to enhance the skin's moisturizing and maintaining function, and is therefore widely used in rash creams and ointments.

[0019] In one aspect of this disclosure, the aforementioned arachidonic acid glucoside is a substance obtained through the condensation reaction of arachidonic acid and glucose. The aforementioned arachidonic acid glucoside helps to soften and supple the skin and contributes to the emulsification and stabilization of other ingredients in cosmetics that do not mix with each other.

[0020] In one aspect of this disclosure, the aforementioned *Chlorophytum comosum* ( Chondrus Crispus Carraigin is a red algae belonging to the genus Carraigin in the family Gigartinaceae. It is also known as horngrass and grows in the rocky areas of the Atlantic coast of Europe and North America. A characteristic of Carraigin is its high content of MAA (mycosporine-like amino acids) components such as Porphyra-334 and Palythene.

[0021] The Carrageenan extract used in this disclosure includes extracts obtained by extracting Carrageenan, dilutes or concentrates of the extracts, dried products obtained by drying the extracts, crude or refined products of the extracts, or mixtures thereof, the extracts themselves, and extracts of all dosage forms that can be formed using the extracts.

[0022] In the extraction of *Chlorophytum comosum* described above, there are no particular limitations on the extraction method; extraction can be performed using methods commonly used in this technical field. Non-limiting examples of the extraction methods described above include hot water extraction, ultrasonic extraction, filtration, or reflux extraction, and these methods can be performed individually or in combination of two or more extraction methods.

[0023] There are no particular limitations on the type of extraction solvent used to extract the above-mentioned *Chlorophytum comosum*, and any solvent known in the art can be used. As non-limiting examples of the extraction solvent, water; lower C1 to C4 alcohols such as methanol, ethanol, propanol, or butanol; polyols such as glycerol, butanediol, or propylene glycol; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, or dichloromethane; or mixtures thereof can be used. Preferably, water, lower alcohols, 1,3-butanediol, and ethyl acetate can be used alone, or a mixture of two or more.

[0024] In one aspect of this disclosure, the above-mentioned Carrageenan extract can be filtered to remove suspended solid particles, for example, by using nylon or other filter particles, or by using freeze filtration, and then used directly or dried by freeze drying, hot air drying, spray drying, or other methods.

[0025] In one aspect of this disclosure, the term "skin barrier" refers to the physical, chemical, or physiological barrier formed by the skin to prevent the invasion of external substances such as pathogens and the outflow of substances, while also preventing chemical or physical damage as well as damage to moisture or minerals. Furthermore, the term "improving the skin barrier" can refer to chemically or biologically restoring a damaged skin barrier, thereby improving the skin's function as a barrier so that it can effectively prevent the invasion of external substances or the outflow of substances. This differs from simply directly replenishing skin moisture or physically preventing moisture loss through skin moisturizing.

[0026] Furthermore, the term "improved skin elasticity" can refer to increased skin elasticity, achieved by inhibiting collagen-degrading enzymes and promoting collagen production, thereby inhibiting or preventing the loss of skin elasticity, or alleviating already reduced elasticity. Additionally, "improved skin barrier or elasticity" can be achieved by increasing the production of fibronectin and collagen, thereby strengthening the skeletal structure of skin cells. This can be achieved by increasing the expression levels of the fibronectin gene (FN1) and the collagen gene (COL1A1) (see Experimental Example 2).

[0027] In one aspect of this disclosure, the content of the above-mentioned active ingredient relative to the total weight of the composition can be from 0.00001 to 50% by weight, preferably from 0.0001 to 0.1% by weight. When the content of the above-mentioned active ingredient is used within the above-mentioned range, the effect can be more superior. Furthermore, relative to the total weight of the composition, the content of each of the above-mentioned PDRN, troxerutin, panthenol, arachidonic acid glucoside, or *Chlorella vulgaris* extract can be from 0.00001 to 50% by weight, preferably from 0.0001 to 0.1% by weight. When the above-mentioned components are included in the composition within the above-mentioned weight ratio range, they can safely and significantly improve the skin barrier or elasticity in humans.

[0028] In one aspect of this disclosure, the above-described composition may contain PDRN and one or more of the following ingredients in a weight ratio of 1:0.1 to 10, preferably 1:0.2 to 5, more preferably 1:0.3 to 3, and even more preferably 1:0.5 to 1.5 (PDRN: one or more selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside, and *Chlorella vulgaris* extract). As described above, when the active ingredient is contained in a specific weight ratio, the synergistic effect on improving the skin barrier or elasticity can be further enhanced.

[0029] In one aspect of this disclosure, the above composition may contain PDRN and arachidonic acid glucoside as active ingredients, and may contain PDRN and arachidonic acid glucoside in a weight ratio of 1:1 to 10, preferably 1:2 to 7, more preferably 1:3 to 5 (PDRN:arachidonic acid glucoside). As described above, when PDRN and arachidonic acid glucoside are contained in a specific weight ratio, the synergistic effect on improving the skin barrier or elasticity can be further enhanced.

[0030] In one aspect of this disclosure, the composition may contain PDRN, troxerutin, and arachidonic acid glucoside as active ingredients, in which case the synergistic effect on improving skin barrier or elasticity is superior. Preferably, the composition may contain PDRN, troxerutin, and arachidonic acid glucoside in a weight ratio of 1:0.1 to 5:0.1 to 10, more preferably 1:0.3 to 3:1 to 8, and more preferably 1:0.5 to 1.5:3 to 6 (PDRN: troxerutin: arachidonic acid glucoside). As described above, when PDRN, troxerutin, and arachidonic acid glucoside are contained in a specific weight ratio, the synergistic effect on improving skin barrier or elasticity can be further enhanced.

[0031] In addition, this disclosure provides a cosmetic composition for improving skin barrier or elasticity, comprising PDRN and one or more of the following as active ingredients: troxerutin, panthenol, arachidonic acid glucoside, and carrageenan extract.

[0032] In one aspect of this disclosure, the cosmetic composition may contain adjuvants commonly found in the field of cosmetics, such as fatty substances, organic solvents, solvents, concentrates, gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion blocking agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic surfactants, or lipid vesicles, and may also contain any other ingredients commonly used in cosmetics.

[0033] In one aspect of this disclosure, the dosage form of the above-mentioned cosmetic composition can be prepared, for example, as a solution, emulsion, suspension, paste, cream, lotion, gel, powder, spray, cleanser containing surfactant, oil, soap, liquid cleanser, bath additive, foundation, makeup base, serum, toner, foam, mask, softening lotion, sunscreen or sun oil, etc. Preferably, the dosage form of the above-mentioned cosmetic composition can be prepared as a topical ointment, softening toner, nourishing toner, nourishing cream, massage cream, serum, mask, emulsion or oil gel, etc.

[0034] In addition, this disclosure provides a topical skin composition for improving skin barrier or elasticity, comprising PDRN and one or more of the group consisting of troxerutin, panthenol, arachidonic acid glucoside and carrageenan extract as active ingredients.

[0035] In one aspect of this disclosure, the aforementioned topical skin formulation can refer to a solid, semi-solid, or liquid topical agent prepared by mixing the active ingredient with various bases such as oils, petrolatum, lanolin, or glycerin, making it easily applicable to the skin. The aforementioned topical dosage form is not particularly limited, but can be a powder, gel, ointment, cream, liquid, or aerosol.

[0036] In one aspect of this disclosure, the above-described composition for improving skin barrier or elasticity can be applied to the face or other body parts via transdermal administration methods such as direct application or spraying onto the skin. The terms "administration" or "application" refer to introducing the composition of this disclosure into the skin by any suitable method. The composition can be administered via any general route, as long as it reaches the target tissue, and can be administered transdermally, preferably topically. The frequency of administration or application of the composition can be appropriately determined according to the user's needs. The dosage of the composition can be appropriately adjusted according to individual differences such as age or skin condition, or dosage form, and typically an appropriate amount can be applied to the skin once or several times a day for one week to several months. In an embodiment of this disclosure, the composition for improving skin barrier or elasticity was used twice a day, morning and evening, for two months, resulting in a significant improvement in skin barrier or elasticity (Experimental Example 4).

[0037] In one aspect of this disclosure, the above-described compositions for improving skin barrier or elasticity can be applied in any form or via a carrier. For example, the compositions can be applied in the form of conventional solutions, dispersions, emulsions, pastes, or powders, and can be used alone or as premixes. Additionally, the compositions can be applied via macroscopic, microscopic, or nanoscale carriers such as capsules, spheres, liposomes, or oleosomes, and can also be applied via nanoscale particles or sponges, or vectors such as nanoemulsions. Furthermore, the compositions can be applied by absorption onto organic polymer powders, talc, bentonite, or other inorganic / organic supports. Additionally, the compositions can be adsorbed or absorbed onto fabrics, natural or synthetic fibers, wool, or clothing or underwear that comes into contact with the skin via macroscopic, microscopic, or nanoscale carriers such as particles or capsules. As described above, the compositions can be adsorbed or absorbed onto fabrics or clothing, etc., and continuously and locally delivered to the skin through contact between the skin and the fabric.

[0038] Additionally, this disclosure provides the use of a composition comprising PDRN and one or more selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside and carrageenan extract for improving skin barrier or elasticity.

[0039] In addition, this disclosure provides a method for preparing a composition for improving skin barrier or elasticity, comprising the steps of mixing PDRN and one or more selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside and carrageenan extract.

[0040] In addition, this disclosure provides a method for improving skin barrier or elasticity, comprising the step of applying a composition comprising PDRN and one or more selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside and carrageenan extract as active ingredients to the skin.

[0041] In one aspect of this disclosure, the method for improving the skin barrier or elasticity described above can apply the composition to the skin such that the dosage of the active ingredient in the composition is 1 to 1000 mg / L, preferably 10 to 500 mg / L. Furthermore, the method can apply the composition to the skin for more than one week, for example, from one day to six months, preferably one week to four months, but the maximum application period is not limited. Additionally, the method can apply the composition to the skin one to six times daily, preferably one to three times daily, for example, twice a day, in the morning and evening.

[0042] All ingredients described in this disclosure preferably do not exceed the maximum usage limits specified in relevant regulations and standards in Korea, China, the United States, Europe, Japan, etc. (e.g., relevant regulations such as cosmetic safety standards (Korea) or cosmetic safety technical specifications (China)). That is, preferably, the cosmetic or topical skin composition according to this disclosure contains the ingredients according to this disclosure within the content limits permitted by the relevant regulations and standards of each country.

[0043] Invention Effects

[0044] The compositions disclosed herein for improving the skin barrier or elasticity exhibit a significant and excellent synergistic effect in improving the skin barrier or elasticity through the combination of specific active ingredients. Therefore, the compositions disclosed herein for improving the skin barrier or elasticity can be effectively used as functional compositions in cosmetics or topical skin agents that target skin tissue. Detailed Implementation

[0045] Hereinafter, to aid in understanding the present invention, detailed descriptions will be provided, including examples. However, embodiments of the present invention can be modified into various other forms, and the scope of the invention should not be construed as limited to the following embodiments. The embodiments of the present invention are provided to provide a more complete explanation of the invention to those skilled in the art.

[0046] Preparation of cosmetic compositions for improving skin barrier or elasticity in Examples 1 to 7

[0047] A skin toner composition was prepared using conventional methods according to the formulations described in Table 1 below, using PDRN, troxerutin, panthenol, arachidonic acid glucoside, and *Chlorella vulgaris* extract. The PDRN used in the following examples was obtained by breaking down salmon DNA and filtering it through a 0.5 μm filter. The *Chlorella vulgaris* extract was obtained by hot water extraction at 100°C. Troxerutin and panthenol were purchased from conventional raw material suppliers and used accordingly.

[0048] [Table 1]

[0049] Experimental Example 1: Enhanced Fibroblast Activity

[0050] Human fibroblasts were purchased from Promocell. These fibroblasts were cultured in DMEM (Hyclone Inc., Utah, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2. The cultured fibroblasts were aliquoted into 96-well plates at 3,000 cells / well and cultured for 24 hours in 0.1% serum. Subsequently, a control group was used for the treatment of cultured cells in serum-free DMEM with DMSO (vehicle) diluted 1:1000, and a positive control group was used for the treatment of Wnt3a 100 ng / mL. The cultured cells were then treated with PDRN, troxerutin, panthenol, arachidonic acid glucoside, and *Chlorella vulgaris* extract at the concentrations described in Table 2 and cultured for one day. After culturing, the degree of cell viability enhancement was evaluated using the CCK method. CCK-8 was added to the culture medium at a ratio of 1:10 and cultured for 1 hour. After 1 hour, the absorbance of each well was measured at 450 nm. All experiments were repeated three times, and the average absorbance values ​​were calculated. The results are presented as a percentage of the control group (100).

[0051] [Table 2]

[0052] Based on the results in Table 2 above, it was confirmed that treatment with PDRN and one or more of the ingredients selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside, and Carrageenan extract significantly enhanced fibroblast activity. Therefore, the composition disclosed herein enhances fibroblast activity, thereby exhibiting significantly superior effects in improving skin barrier function and skin elasticity.

[0053] Experimental Example 2: Gene Regulation Effects in Fibroblasts Related to Improved Skin Barrier or Elasticity

[0054] Fibronectin and collagen, which constitute the cytoskeleton, play important roles in skin barrier function and elasticity. The FN1 and COL1A1 genes are known to play important roles in skin barrier function and elasticity by encoding one type of fibronectin or collagen. Therefore, the effects of PDRN, troxerutin, panthenol, arachidonic acid glucoside, *Chlorella vulgaris* extract, or mixtures thereof disclosed in this invention on the expression of the above-mentioned genes in fibroblasts were investigated.

[0055] Hair papilla cells were divided into 1×10 5100 cells / well were seeded into each well of a 6-well plate, and then, as described in Table 4 below, were seeded at 100 mg / well. PDRN, troxerutin, panthenol, arachidonic acid glucoside, *Chlorella vulgaris* extract, or mixtures thereof were used to treat the cells. The expression levels of FN1 and Col1A1 were detected using real-time PCR, and the results are shown in Table 4 below. The Taqman® probes (Thermo Fisher, Massachusetts, USA) used in the above real-time PCR are listed in Table 3 below.

[0056] [Table 3]

[0057] [Table 4]

[0058] Based on the results in Table 4 above, it was confirmed that treatment with PDRN and one or more combinations selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside, and Carrageenan extract significantly increased the expression levels of the FN1 and COL1A1 genes. Therefore, the composition disclosed herein increases the synthesis of fibronectin and collagen, which constitute the cytoskeleton, thereby exhibiting significantly superior effects in improving skin barrier function and skin elasticity.

[0059] Experimental Example 3: Enhanced Wound Healing Effect in Fibroblasts

[0060] Human fibroblasts were purchased from Promocell. These fibroblasts were cultured in DMEM (Hyclone Inc., Utah, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2. The cultured fibroblasts were aliquoted at 80,000 cells / well into 6-well plates and cultured for 24 hours in 0.1% serum. Subsequently, after uniformly creating wounds between the plates using a metal tip, the cultured cells were treated with a 1:1000 diluted DMSO (vehicle) solution in serum-free DMEM as a control group. As a positive control group, the following treatments were used: PDRN, troxerutin, panthenol, arachidonic acid glucoside, *Chlorella vulgaris* extract, or mixtures thereof, and cultured for one day, as described in Table 5 below. Images of the changes in the wound area before and after culture were acquired using a 200x microscope and then quantified using ImageJ. All experiments were repeated three times, and the average reduction in wound area was calculated. The results are presented as a percentage of the control group (100) relative to the treatment group.

[0061] [Table 5]

[0062] Based on the results in Table 5 above, it was confirmed that treatment with PDRN and one or more combinations selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside, and Carrageenan extract significantly enhanced in vitro wound healing. Therefore, the compositions disclosed herein significantly enhance wound healing in fibroblasts, thereby exhibiting significantly superior skin barrier and skin elasticity improvement effects.

[0063] Experimental Example 4: Confirmation of the efficacy of compositions for improving skin barrier or elasticity

[0064] The skin barrier or elasticity improvement effects of the disclosed compositions for improving skin barrier or elasticity were tested on 35 subjects, both men and women. The skin toner compositions of Comparative Example 1 and Examples 1 to 7 were used to conduct a total of 2 months of efficacy testing for improving skin barrier or elasticity.

[0065] The testing was conducted before and two months after the product was used. Furthermore, during the human application testing period, all cosmetics containing active ingredients that might affect the skin barrier or elasticity were prohibited, except for the test product. Subjects used the test product twice a day, morning and evening, for two months.

[0066] To determine the skin barrier improvement effect, after cleansing, the skin was kept at a constant temperature and humidity (25°C, 40% relative humidity) for 10-15 minutes, and the measurement was taken for 10-15 seconds in the std mode using a Vapometer (EP1, Delfin Technologies Ltd, 70211 Kuopio, FINLAND) while at rest. The experiment was repeated 3 times and the average value was calculated.

[0067] The improvement in skin elasticity was measured using a cutometer (Cutometer® dual MPA580 from Courage + Khazaka electronic GmbH) with negative pressure. Skin elasticity was measured on the same forehead area of ​​the subjects before and after using the test product. The experiment was repeated three times and the average value was calculated. The results are shown in Table 6 below.

[0068] [Table 6]

[0069] Based on the results in Table 6 above, it was confirmed that when PDRN and one or more combinations selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside, and chondrus crispus extract were applied to actual skin, a significant increase in improving skin barrier function or elasticity was observed. Therefore, the compositions disclosed herein can be used very effectively to improve skin barrier function or elasticity.

[0070] In this disclosure, the above-described embodiments were prepared into a skin toner formulation, thereby confirming an effect of improving the skin barrier or elasticity. However, this dosage form example is merely one example of the compositions of this disclosure for improving the skin barrier or elasticity, and the scope of the compositions of this disclosure is not limited to this dosage form, as will be apparent to those skilled in the art to which this invention pertains.

Claims

1. A composition for improving skin barrier or elasticity, comprising PDRN (polydeoxyribonucleotide) and one or more of the following as active ingredients: troxerutin, panthenol, arachidyl glucoside, and Chondrus crispus extract.

2. The composition for improving skin barrier or elasticity according to claim 1, wherein, The aforementioned PDRN is a DNA fragment extracted from the testes of salmonid fish, with a molecular weight ranging from 5 to 4000 kDa.

3. The composition for improving skin barrier or elasticity according to claim 1, wherein, The content of the above-mentioned active ingredient is 0.00001 to 50% by weight relative to the total weight of the composition.

4. The composition for improving skin barrier or elasticity according to claim 1, wherein, The above composition contains PDRN and one or more of the following ingredients in a weight ratio of 1:0.1 to 10 (PDRN: selected from the group consisting of troxerutin, panthenol, arachidonic acid glucoside and Carrageenan extract).

5. The composition for improving skin barrier or elasticity according to claim 1, wherein, The above composition contains PDRN and arachidonic acid glucoside as active ingredients, and the PDRN and arachidonic acid glucoside are contained in the above composition in a weight ratio of 1:1 to 10 (PDRN:arachidonic acid glucoside).

6. The composition for improving skin barrier or elasticity according to claim 1, wherein, The above composition contains PDRN, troxerutin and arachidonic acid glucoside as active ingredients, and the above PDRN, troxerutin and arachidonic acid glucoside are contained in the above composition in a weight ratio of 1:0.1 to 5:0.1 to 10 (PDRN: troxerutin: arachidonic acid glucoside).

7. The composition for improving skin barrier or elasticity according to claim 1, wherein, The above composition is a cosmetic or topical skin agent.

Images